




Using Central Monitoring to Mitigate Data Quality Risk During the COVID-19 Pandemic


PHUSE US Connect 2021

Coronavirus 2019-nCov novel coronavirus

Anna Wojcik – Central Monitoring Manager
Risk Management-Central Monitoring
Janssen R&D

Note: Presentations are intended for informational purposes only and do not replace independent professional judgment. Statements of fact and opinions expressed are those of the speakers only and are not the opinion or position of the Janssen Research and Development, LLC or its affiliates.

What We'll Cover Today...



Risk Management-Central Monitoring at Janssen R&D



Monitoring Strategy Risk Analysis



Monitoring Strategies to Mitigate COVID-19 Impact




Conclusions

Risk Management-Central Monitoring at Janssen R&D


Risk Management-Central Monitoring Evolution in ARBM Studies & Central Monitoring Managers



of Studies using ARBM approach (cumulative)



Total number of CMM in RMCM department



RMCM department formed in 2013. We now have 100+ Central Monitoring Managers (CMMs) and are growing!

Note: Presentations are intended for informational purposes only and do not replace independent professional judgment. Statements of fact and opinions expressed are those of the speakers only and are not the opinion or position of the Janssen Research and Development, LLC or its affiliates.

Monitoring Strategy Risk Analysis

Monitoring Strategy Risk Analysis

Impact of COVID-19

For study participants, site personnel & site monitors:

- Travel Restrictions
- Health Concerns
- Competing priorities


For Sponsors:

- Missing data & data quality concerns
- Source Data Verification (SDV) & Source Document Review (SDR) backlog

Risk Analysis Guidance:

- ✓ Assists in determining monitoring strategy changes to mitigate COVID-19 impact
- ✓ Maximizes the use of technology and resources to oversee subject safety and data quality centrally and remotely
- ✓ Standardized Risk Analysis Packages (RAP) to provide central monitoring support for trials previously out of scope and augment support for trials in scope of Analytical Risk Based Monitoring

Monitoring Strategy Risk Analysis: What to Consider?




note


This list is not comprehensive; any other important study-specific considerations should also be incorporated into the risk analysis

Monitoring Strategies to Mitigate COVID-19 Impact


Monitoring Strategy to Mitigate COVID-19 Impact




Source Data Verification (SDV) *example of targeted SDV reduction*




Example study: Pending SDV pages dropped in November 2020 due to tSDV reduction from 31% to 25%



Source Document Review (SDR) *example of targeted SDR reduction*



Example study: Implementation of targeted SDR Requirements




- Reduce SDR to 1 out of every 3 enrolled subjects for 100% SDR
- SM reviews subjects in Batches of 3 (3-subjects group)
- If the first SDR subject in a batch has an area of concern the SM would choose a second subject for 100% SDR in the same batch

Central Monitoring *example of Risk Analysis Package*

Includes reviews of:

- ✓ Site profile Tool
 - ✓ Protocol deviation trending
 - ✓ COVID-19 Protocol deviations
 - ✓ Query Trending
 - ✓ Study Issues
 - ✓ Adverse Events reporting
 - ✓ SDV Trending
 - ✓ Time to data Entry
 - ✓ Trial Disposition Trending
- Leverages available data from Single Central Monitoring Dashboard (EDC and CTMS datasource)
 - Analyses planned to be conducted monthly, frequent can change per study needs
 - Central Monitoring Managers (CMMs) from the Risk Management-Central Monitoring group (RM-CM) will conduct the reviews and provide to Study Teams for central oversight during pandemic



Central Monitoring *example of Risk Analysis Package*

Protocol Deviations

- Description of key trends observed



COVID-19 Protocol Deviations

- Description of key trends observed

Time to Data Entry

- Description of key trends observed

Query Trending

- Description of key trends observed



Study Issues

- Description of key trends observed

Adverse Events

- Description of key trends observed

SDV Trending

- Description of key trends observed

Trial Disposition Trending

- Description of key trends observed


Site Profile Tool

- Description of key trends observed


Adverse Events Metrics

An overview of time to AE entry, assessed for changes over time and YOY. Cumulative & Rate


Adverse Event Accumulation severity and Covid-19 relatedness | Trial Assessment



Adverse Event | Total AE cumulative , Only COVID-19




Adverse Event | Total AE over time , Only COVID-19




COVID-19 Related Protocol Deviation Trending

Algorithm learns what words/sets of words belong to each category for example Covid-PD related


COVID-19 PD Distribution | Overall over Time




COVID-19 PD Distribution | Sub-Categories Over Time



Protocol Deviation Distribution | Protocols



COVID-19 PD Distribution | Protocols Sub-Categories



LEGEND

- Concomitant medication
- Did not satisfy inclusion/exclusion
- Dose out of window/missed
- Exam/Procedure by unqualified person
- Exam/Procedure incorrect/out of order
- Exam/procedure not done
- Incorrect dose/wrong IP
- Informed Consent Form
- IP not stored properly
- IP procedure not correct
- No description
- Patient did not follow IP procedure
- Patient not compliant with IP
- Patient not taken off study drug
- Questionnaire not done
- Questionnaire out of window
- SAE not reported on time
- Sample not collected
- Sample other
- Visit missed
- Visit out of window

Comments


A Natural Language Processing application has been used to apply a sub-category to all protocol deviations. They are then grouped into a higher level of categories, where one category is 'COVID-19 related'.

- COVID-19 PDs keeps decreasing in time. 'Sample collected' is most used subcategory.


Source Data Verification [SDV] Metrics

The total pending pages to be source data verified are assessed for difference from study baseline and potential risks to study deliverables.


SDV Activity | Study Over Time



Projected Future SDV | Study Over Time (In-house studies only)



Pending Source Data Verification | Countries Overall



Risk Score Trend Review

Calculation: Roll-up Score = (# green sites + 0.5*(# amber sites))/ (# green sites + # amber sites + # red sites)

Total # Red Sites




50

Total # Amber Sites

391

Total # Green Sites

548



Comments

Slightly decreasing percentage of green sites from April in 2020

Site Profile Tool: holistic analysis based upon 15 KRIs (Data Management, Subject Management, Site Management) built upon centrally available data.

Conclusions

MSRA and RAP Benefits and Conclusions

2021

- **RAP can be quickly adapted and relaunch for specific Therapeutic Area, Compound, Trial, country or site level.** *COVID 19 MAY GO AWAY, BUT THE RAP IS HERE TO STAY.*
- **Cross functional** approach to **pro-actively identify potentially high-risk sites** to **quickly mitigate risk** in study conduct.
- Strategy will help study teams maintain **trial oversight** through **ongoing and continuous review** of **information, trends and metrics**
- Increasing frequency of reviews during pandemic period will keep high **quality by focusing** on subject **safety and critical data** and **reducing errors that matter**
- Moved from 30% to 70% off site monitoring, reduced Site Manager workload due to tSDV reduction and tSDR implementation
- Preventing delay of planned data base lock milestone

Thank you



| PHARMACEUTICAL COMPANIES
OF *Johnson & Johnson*